Analysis on utilization of antitumor platinum drugs in 21 hospitals of Chengdu from 2011 to 2014_West China Medical Journal

Authors：

ZHOU Mingyong ,  ZHENG Yongchi

Department of Pharmacy, Dujiangyan People’s Hospital, Dujiangyan, Sichuan 611830, P. R. China;

Corresponding?author：

ZHENG Yongchi, Email: 1121677611@qq.com

Keywords：

Platinum drugs; Cisplatin; Consumption sum; Frequency of drug use; Defined daily cost

DOI：

10.7507/1002-0179.201604216

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the utilization of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014. Methods The utilization information of platinum drugs in 21 hospitals of Chengdu from 2011 to 2014 was extracted, and the dosage form of drugs, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2011 to 2014, the total consumption sums and DDDs of platinum drugs were increased year by year. The consumption sums of oxaliplatin were the highest, and the consumption sums of carboplatin were increased year by year. Oxaliplatin, nedaplatin, and lobaplatin were ranked first, second and fifth respectively in all the four consecutive years; the total DDDs of patinum drugs from 2011 to 2014 showed a trend of increase, DDDs of cisplatin were always ranked first, followed by oxaliplatin; DDC and sorting of platinum drugs were relatively stable, and B/A values of carboplatin and cisplatin were close to 1.00. Conclusion The utilization of platinum drugs in 21 hospitals of Chengdu is in accordance with the principle of safety, effectiveness, economy and convenience.

Citation： ZHOU Mingyong, ZHENG Yongchi. Analysis on utilization of antitumor platinum drugs in 21 hospitals of Chengdu from 2011 to 2014. West China Medical Journal, 2017, 32(8): 1247-1250. doi: 10.7507/1002-0179.201604216 Copy

1.	Rosenberg B, Camp V, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem, 1967, 242(6): 1347-1352.
2.	張建忠, 柯櫻, 沈佳琳. 鉑類抗腫瘤藥物的研發進展及市場情況. 上海醫藥, 2013, 34(23): 52-59.
3.	巫劍峰, 董淑英, 武丹丹, 等. Pannexin1 通道在順鉑誘導睪丸癌 I-10 細胞凋亡中的作用. 南方醫科大學學報, 2016, 36(11): 1456-1460.
4.	Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology, 2012, 153(4): 1593-1602.
5.	李莉, 王友群, 孫蔚莉, 等. 含鉑方案治療晚期乳腺癌臨床研究. 中華腫瘤防治雜志, 2016, 23(10): 657-662.
6.	Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem Rev, 2016, 116(5): 3436-3486.
7.	陳新謙, 金有豫, 湯光. 新編藥物學. 17 版. 北京: 人民衛生出版社, 2011: 721-722.
8.	Qian W, Salamoun J, Wang J, et al. The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. Bioorg Med Chem Lett, 2015, 25(4): 856-863.
9.	Resende HM, Jacob L, Quinellato LV, et al. Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database Syst Rev, 2015, 10: CD008531.
10.	Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 2005, 117(2): 294-299.
11.	Huang ZL, Cao X, Luo RZ, et al. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: a prospective study. Oncol Lett, 2016, 11(1): 299-305.
12.	Wang H, Zhu X, Huang J, et al. Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells. Oncol Lett, 2016, 11(4): 2566-2572.
13.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
14.	陳萬青, 鄭榮壽, 曾紅梅, 等. 2011 年中國惡性腫瘤發病和死亡分析. 中國腫瘤, 2015, 24(1): 1-10.
15.	李小梅, 鄭詠池. 2011-2014 年成都地區 21 家醫院抗腫瘤藥物使用情況分析. 中國醫院藥學雜志, 2016, 36(15): 1319-1322.

1. Rosenberg B, Camp V, Grimley EB, et al. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem, 1967, 242(6): 1347-1352.
2. 張建忠, 柯櫻, 沈佳琳. 鉑類抗腫瘤藥物的研發進展及市場情況. 上海醫藥, 2013, 34(23): 52-59.
3. 巫劍峰, 董淑英, 武丹丹, 等. Pannexin1 通道在順鉑誘導睪丸癌 I-10 細胞凋亡中的作用. 南方醫科大學學報, 2016, 36(11): 1456-1460.
4. Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology, 2012, 153(4): 1593-1602.
5. 李莉, 王友群, 孫蔚莉, 等. 含鉑方案治療晚期乳腺癌臨床研究. 中華腫瘤防治雜志, 2016, 23(10): 657-662.
6. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem Rev, 2016, 116(5): 3436-3486.
7. 陳新謙, 金有豫, 湯光. 新編藥物學. 17 版. 北京: 人民衛生出版社, 2011: 721-722.
8. Qian W, Salamoun J, Wang J, et al. The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. Bioorg Med Chem Lett, 2015, 25(4): 856-863.
9. Resende HM, Jacob L, Quinellato LV, et al. Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database Syst Rev, 2015, 10: CD008531.
10. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 2005, 117(2): 294-299.
11. Huang ZL, Cao X, Luo RZ, et al. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: a prospective study. Oncol Lett, 2016, 11(1): 299-305.
12. Wang H, Zhu X, Huang J, et al. Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells. Oncol Lett, 2016, 11(4): 2566-2572.
13. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
14. 陳萬青, 鄭榮壽, 曾紅梅, 等. 2011 年中國惡性腫瘤發病和死亡分析. 中國腫瘤, 2015, 24(1): 1-10.
15. 李小梅, 鄭詠池. 2011-2014 年成都地區 21 家醫院抗腫瘤藥物使用情況分析. 中國醫院藥學雜志, 2016, 36(15): 1319-1322.

West China Medical Journal

Analysis on utilization of antitumor platinum drugs in 21 hospitals of Chengdu from 2011 to 2014

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content